Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.

A prespecified secondary analysis of the DAPHNe trial assessed 5-year outcomes and ultrasensitive ctDNA dynamics in ERBB2-positive breast cancer treated with neoadjuvant paclitaxel, trastuzumab, and pertuzumab. A Personalis author affiliation is on the PubMed record.

JAMA OncologyPubMed 42348190DOI 10.1001/jamaoncol.2026.2023